Buscar
Mostrando ítems 1-10 de 260
Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis
(Elsevier B.V., 1999-08-05)
A natural low molecular weight heparin (8.5 kDa), with an anticoagulant activity of 95 IU/mg by the USP assay, was isolated from the shrimp Penaeus brasiliensis. the crustacean heparin was susceptible to both heparinase ...
Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients
Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney.
Reports suggest a beneficial effect of the use of heparin/low molecular weight heparin (LMWH) on mortality
in ...
Extensive Skin Necrosis Induced by Low-Molecular-Weight Heparin in a Patient With Systemic Lupus Erythematosus and Antiphospholipid Syndrome
(Lippincott Williams & WilkinsPhiladelphiaEUA, 2012)
Heparins and heparinoids: Occurrence, structure and mechanism of antithrombotic and hemorrhagic activities
(Bentham Science Publ Ltd, 2004-01-01)
The correlation between structure, anticloting, antithrombotic and hemorrhagic activities of heparin, heparan sulfate, low molecular weight heparins and heparin-like compounds from various sources that are in used in ...
US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparins
(SPRINGERDORDRECHT, 2012)
Low-molecular-weight heparins (LMWHs) have shown equivalent or superior efficacy and safety to unfractionated heparin as antithrombotic therapy for patients with acute coronary syndromes. Each approved LMWH is a pleotropic ...
Anticoagulantes: Farmacología, mecanismos de acción y usos clínicos
(Instituto de Cirugía de la Facultad de Medicina de la Universidad Austral de Chile y el Servicio de Cirugía del Hospital Clínico Regional de Valdivia, 2018)
Combinations of low doses of unfractionated heparin and of low-molecular-weight heparin prevent experimental venous thrombosis
(Karger, 2005-01-01)
Synergism between low-molecular-weight heparin and low doses of unfractionated heparin (UH) enhancing anti-factor Xa activity and the release of tissue factor pathway inhibitor was observed. The aim of this study was to ...
Combinations of low doses of unfractionated heparin and of low-molecular-weight heparin prevent experimental venous thrombosis
(Karger, 2005-01-01)
Synergism between low-molecular-weight heparin and low doses of unfractionated heparin (UH) enhancing anti-factor Xa activity and the release of tissue factor pathway inhibitor was observed. The aim of this study was to ...